The association of Hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 3, 2003, Pages 356-364

  Strasfeld, Lynne ^a   Lo, Yungtai ^a   Netski, Dale ^b   Thomas, David L ^b   Klein, Robert S ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug users; HCV; Hepatitis C virus; RNA level; Viral load

Indexed keywords

CD4 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; T LYMPHOCYTE; UNITED STATES; VIRUS DETECTION; VIRUS LOAD;

EID: 0037488418     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200307010-00010     Document Type: Article

References (44)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-662.
2. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board. Antwerp, Belgium. J Viral Hepat. 1999;6:35-47.
3. Garfein RS, Doherty MC, Monterroso ER, et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immun Defic Syndr. 1998;18(suppl 1): S11-S19.
4. Quan CM, Krajden M, Grigoriew GA, et al. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1993;17:117-119.
5. van den Hoek JAR, van Haastrecht HJA, Goudsmit J, et al. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis. 1990;162:823-826.
6. Donahue JG, Nelson KE, Munoz A, et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol. 1991;134:1206-1211.
7. Williams I. Epidemiology of hepatitis C in the United States. Am J Med. 1999;107(6B):2S-9S.
8. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296-305.
9. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
10. Dorrucci M, Pezzotti P, Phillips AN, et al. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. J Infect Dis. 1995;172:1503-1508.
11. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
12. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis virus genotype and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol. 1997;92:1130-1134.
13. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562-569.
14. Thomas DL, Rich JD, Schuman P, et al. Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis. 2001;183:973-976.
15. Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis. 2000;181:844-851.
16. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injection drug users. J Infect Dis. 1996;174:690-695.
17. Sherman KE, O'Brien J, Gutierrez AG, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol. 1993;31:2679-2682.
18. Eyster ME, Fried MW, Di Bisceglie AM, et al. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood. 1994;84:1020-1023.
19. Daar ES, Lynn H, Donfield S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immun Defic Syndr. 2001;26:466-472.
20. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS. 1995;9:1131-1136.
21. Picchio GR, Nakatsuno M, Boggiano C, et al. Hepatitis C (HCV) genotype and viral titer distribution among Argentinean hemophiliac patients in the presence or absence of human immunodeficiency virus (HIV) co-infection. J Med Virol. 1997;52:219-225.
22. McGuinness PH, Bishop GA, Painter DM, et al. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology. 1996;23:676-687.
23. Chambost H, Gerolami V, Halfon P, et al. Persistent hepatitis C virus RNA replication in haemophiliacs: role of co-infection with human immunodeficiency virus. Br J Haematol. 1995;91:703-707.
24. Ghany MG, Leissinger C, Lagier R, et al. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis Sc. 1996;41:1265-1272.
25. Toyoda H, Fukuda Y, Koyama Y, et al. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. J Hepatol. 1997;26:975-982.
26. Berger A, Depka Prondzinski MV, Doerr HW, et al. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol. 1996;48:339-343.
27. Kobayashi M, Tanaka E, Sodeyama T, et al. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology. 1996;23:695-699.
28. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology. 1994;19:13-18.
29. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992;327:1697-1703.
30. Ray SC, Arthur RR, Carella A, et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis. 2000;182:698-707.
31. Rooney G, Gilson RJC. Sexual transmission of hepatitis C virus infection. Sex Transm Infect. 1998;74:399-404.
32. Thomas DL, Cannon RO, Shapiro CN, et al. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among nonintravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis. 1994;169:990-995.
33. Alter MJ. Hepatitis C virus infection in the United States. J Hepatology. 1999;31(suppl 1):88-91.
34. Chamot E, Hirschel B, Wintsch J, et al. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS. 1990;4:1275-1277.
35. Sorbi D, Shen D, Lake-Bakaar G. Influence of HIV disease on serum anti-HCV antibody titers: a study of intravenous drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:295-296.
36. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr. 2001;26:340-344.
37. Thio CL, Nolt K R, Astemborski J, et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol. 2000;38:575-577.
38. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet. 2002;359:1478-1483.
39. Mathei C, Buntinx F, Van Damme P. Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age? J Infect Dis. 2001;184:659-660.
40. Eyster ME, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Mulicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1993;6:602-610.
41. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 1999;30:1054-1058.
42. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infect Dis. 2002;34:831-837.
43. Mellor J, Hawkins A, Simmonds P. Genotype dependence of hepatitis C viral load measurement in commercially available quantitative assays. J Clin Microbiol. 1999;37:2525-2532.
44. Martinot-Peignoux M, Breton V, Fritsch S, et al. Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays. J Clin Microbiol. 2000;38:2722-2725.